Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma.
Khalid AB, Fountzilas C, Burney HN, Mamdani H, Schneider BP, Fausel C, Perkins SM, Jalal S. Khalid AB, et al. Among authors: fountzilas c. Front Oncol. 2024 Nov 21;14:1435056. doi: 10.3389/fonc.2024.1435056. eCollection 2024. Front Oncol. 2024. PMID: 39640282 Free PMC article.
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS; MOUNTAINEER investigators. Strickler JH, et al. Among authors: fountzilas c. Lancet Oncol. 2023 May;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X. Lancet Oncol. 2023. PMID: 37142372 Clinical Trial.
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer.
Gardner FP, Wainberg ZA, Fountzilas C, Bahary N, Womack MS, Macarulla T, Garrido-Laguna I, Peterson PM, Borazanci E, Johnson M, Ceccarelli M, Pelzer U. Gardner FP, et al. Among authors: fountzilas c. Cancers (Basel). 2024 Mar 28;16(7):1323. doi: 10.3390/cancers16071323. Cancers (Basel). 2024. PMID: 38611000 Free PMC article.
Models using comprehensive, lesion-level, longitudinal [68Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [177Lu]Lu-DOTA-TATE.
Santoro-Fernandes V, Schott B, Deatsch A, Keigley Q, Francken T, Iyer R, Fountzilas C, Perlman S, Jeraj R. Santoro-Fernandes V, et al. Among authors: fountzilas c. Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3428-3439. doi: 10.1007/s00259-024-06767-x. Epub 2024 May 25. Eur J Nucl Med Mol Imaging. 2024. PMID: 38795121
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD. Chiorean EG, et al. Among authors: fountzilas c. J Natl Compr Canc Netw. 2023 Jul;21(7):753-782. doi: 10.6004/jnccn.2023.0034. J Natl Compr Canc Netw. 2023. PMID: 37433437
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Mahalingam D, Hanni S, Serritella AV, Fountzilas C, Michalek J, Hernandez B, Sarantopoulos J, Datta P, Romero O, Pillai SMA, Kuhn J, Pollak M, Thompson IM. Mahalingam D, et al. Among authors: fountzilas c. Oncotarget. 2023 Jun 19;14:622-636. doi: 10.18632/oncotarget.28458. Oncotarget. 2023. PMID: 37335291 Free PMC article. Clinical Trial.
Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Mahalingam D, Hanni S, Serritella AV, Fountzilas C, Michalek J, Hernandez B, Sarantopoulos J, Datta P, Romero O, Achutan Pillai SM, Kuhn J, Pollak M, Thompson IM. Mahalingam D, et al. Among authors: fountzilas c. Oncotarget. 2023 Oct 19;14:890-892. doi: 10.18632/oncotarget.28530. Oncotarget. 2023. PMID: 37861386 Free PMC article. No abstract available.
Phase II Study of Nanoliposomal Irinotecan (Nal-IRI) with 5-Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of Gastroenteropancreatic (GEP) or Unknown Origin.
Mukherjee S, Pattnaik H, Sonti S, Ramesh M, Jain P, Ramirez RA, Fountzilas C, Vadehra D, Attwood K, Iyer R. Mukherjee S, et al. Among authors: fountzilas c. Cancers (Basel). 2025 Jan 12;17(2):224. doi: 10.3390/cancers17020224. Cancers (Basel). 2025. PMID: 39858006 Free PMC article.
66 results